Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193466
Phase
PHASE2
Status
Completed

Conditions

  • Non-Hodgkins Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
  • Fludarabine — DRUG
  • CAMPTH-1H — DRUG

Study Details

In this multicenter trial, we will investigate the use of fludarabine plus rituximab, followed by Campath-1H, in previously untreated patients with CLL/SLL. Patients who are elderly, or who are considered unlikely to tolerate this combination therapy well, will receive single agent rituximab followed by Campath-1H.

Key Dates

Start date
Jan 31, 2002
Status verified
Dec 2010
Primary completion
Jan 31, 2007
Completion
Apr 30, 2008

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Complete response rate

Related Studies